For example, tozasertib, a pan-aurora kinase inhibitor inhibiting aurora kinases, FLT3 and BCR-ABL, showed greater antitumor activity in patients with BCR-ABL T351I-mutated chronic myelogenous leukemia (CML) (44% showed hematologic responses) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) (33% showed complete remission)73. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.